Nasdaq: Oramed Unit, Genomma Lab Join To Commercialize Oral COVID-19 Vaccine Candidate In Mexico

Oramed Pharmaceuticals Inc. (ORMP) and Genomma Lab Internacional announced the formation of a 50/50 joint venture between Genomma Lab and Oramed’s majority-owned subsidiary Oravax Medical to develop and commercialize Oravax’s COVID-19 vaccine candidate in Mexico. Oramed and Genomma Lab also announced their plans to enter into a $20 million share swap. Genomma Lab has also committed to participate in a future investment in Oravax. Read more here.

You may also be interested

Join our mailing list

Skip to content